Q2 2024 EPS Estimates for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Lifted by Capital One Financial

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) – Research analysts at Capital One Financial raised their Q2 2024 earnings per share (EPS) estimates for shares of Amphastar Pharmaceuticals in a report issued on Wednesday, May 22nd. Capital One Financial analyst T. Chiang now expects that the company will earn $0.73 per share for the quarter, up from their previous forecast of $0.72. The consensus estimate for Amphastar Pharmaceuticals’ current full-year earnings is $3.60 per share. Capital One Financial also issued estimates for Amphastar Pharmaceuticals’ Q3 2024 earnings at $0.96 EPS and Q4 2024 earnings at $1.02 EPS.

AMPH has been the topic of several other research reports. StockNews.com raised shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, May 13th. JPMorgan Chase & Co. started coverage on shares of Amphastar Pharmaceuticals in a research report on Tuesday, March 5th. They set an “overweight” rating and a $60.00 target price on the stock. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Wednesday, May 22nd. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, Amphastar Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $66.00.

Amphastar Pharmaceuticals Price Performance

AMPH stock opened at $43.26 on Monday. The stock has a market cap of $2.12 billion, a PE ratio of 14.97, a P/E/G ratio of 0.89 and a beta of 0.85. Amphastar Pharmaceuticals has a 12 month low of $38.43 and a 12 month high of $67.66. The company has a 50-day moving average price of $42.10 and a 200 day moving average price of $50.46. The company has a current ratio of 2.18, a quick ratio of 1.72 and a debt-to-equity ratio of 0.88.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its earnings results on Wednesday, February 28th. The company reported $0.81 EPS for the quarter, missing analysts’ consensus estimates of $0.84 by ($0.03). Amphastar Pharmaceuticals had a return on equity of 29.17% and a net margin of 22.88%. The firm had revenue of $178.11 million during the quarter, compared to analysts’ expectations of $174.90 million.

Insiders Place Their Bets

In other Amphastar Pharmaceuticals news, Director Michael A. Zasloff sold 12,500 shares of Amphastar Pharmaceuticals stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $47.18, for a total transaction of $589,750.00. Following the sale, the director now owns 21,326 shares of the company’s stock, valued at approximately $1,006,160.68. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Over the last ninety days, insiders sold 14,000 shares of company stock worth $655,145. Company insiders own 27.10% of the company’s stock.

Institutional Trading of Amphastar Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Exchange Traded Concepts LLC raised its stake in shares of Amphastar Pharmaceuticals by 0.8% in the 4th quarter. Exchange Traded Concepts LLC now owns 21,440 shares of the company’s stock valued at $1,326,000 after acquiring an additional 169 shares during the period. Quadrant Capital Group LLC increased its stake in Amphastar Pharmaceuticals by 27.8% during the 4th quarter. Quadrant Capital Group LLC now owns 1,026 shares of the company’s stock worth $63,000 after buying an additional 223 shares during the period. Bridge City Capital LLC increased its stake in Amphastar Pharmaceuticals by 0.8% during the 1st quarter. Bridge City Capital LLC now owns 34,773 shares of the company’s stock worth $1,527,000 after buying an additional 275 shares during the period. Los Angeles Capital Management LLC boosted its position in Amphastar Pharmaceuticals by 1.3% in the 3rd quarter. Los Angeles Capital Management LLC now owns 27,443 shares of the company’s stock valued at $1,262,000 after buying an additional 358 shares during the period. Finally, Nations Financial Group Inc. IA ADV grew its stake in shares of Amphastar Pharmaceuticals by 2.7% in the first quarter. Nations Financial Group Inc. IA ADV now owns 14,923 shares of the company’s stock worth $655,000 after acquiring an additional 399 shares in the last quarter. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.